SeaSpine and Alphatec are similarly-sized medical device companies that feature a robust product offering.
Recently, SeaSpine released its preliminary financial results for the third quarter of 2018. The spine company expects to generate between $35.5 million and $36 million, a 12 percent to 13 percent increase year-over-year.
Marea Informative compared Alphatec and SeaSpine based on analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.
When looking at volatility and risk, SeaSpine's beta sits at 0.46, with a share price 54 percent less volatile than the S&P 500. Alphatec has a share price 23 percent more volatile than the S&P 500 with a beta of 1.23. Both companies recorded negative net margins for 2017. Alphatec recorded -3.32 percent while SeaSpine recorded -21.75 percent.
Institutional investors own 53.4 percent of SeaSpine Shares while 21.5 percent of Alphatec's shares are owned by institutional investors. With institutional ownership, money managers and hedge funds are certain companies will outperform the market in the long-term, according to Marea Informative.
SeaSpine and Alphatec are even when comparing analysts' ratings. Both sit at 3.00. Alphatec has a $5.50 price target, a potential 80.9 percent upside. Similarly, SeaSpine has a $19.40 price tag, suggesting an 8.14 percent potential upside.
At the end of 2017, SeaSpine recorded $131.8 million in gross revenue. Alphatec recorded $101.7 million in gross revenue. While Alphatec had a lower revenue, the company had higher earnings than SeaSpine.
In summary, Marea Informative indicated Alpahtec performed better than SeaSpine in seven of the 13 factors compared.
To view the full comparison report, click here.